How Calais was paid
$373,808 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Total |
|---|---|---|---|
| Philippe P. CalaisChief Executive Officer | $123,808 | $250,000 | $373,808 |
| Thomas A. FitzgeraldVice President, Chief Financial Officer, and former interim Chief Executive Officer | $480,000 | $589,615 | $1,069,615 |
What changed and why
- $374K$373,808 was CEO Philippe Calais’s 2025 total compensation, including a $250,000 bonus.
- $1.1M$1,069,615 was CFO Thomas Fitzgerald’s 2025 total compensation, including $589,615 in bonuses.
- $480K$480,000 was Fitzgerald’s 2025 salary despite a planned reduction to $440,000 effective October 2025.
- $340K$339,615 comprised Fitzgerald’s two separate 2025 special bonus payments.
- No equity awards were granted to named executive officers during 2025.
- 50%50% and 35% were the target bonus percentages for Calais and Fitzgerald, respectively.
Other Transcode Therapeutics proxy statements
- 2025 proxy statement
Thomas A. Fitzgerald paid $956,966 (+124% on the year).
Filed Jul 15, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.